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See Article, pages 682–689Development of portal vein thrombosis (PVT) is a
signiﬁcant milestone in the natural history of cirrhosis.
It is associated with worsening liver function, ascites,
and the occurrence of gastroesophageal variceal bleed-
ing. However, previous studies have been cross-sectional
in design, and therefore have not been able to address
whether this association is causal (i.e. PVT actually
causes decompensation) or whether the development
of PVT is only a further consequence of advanced liver
disease. On the other hand, it is clear that PVT increases
morbidity and mortality associated with liver transplant
and may even contraindicate it [1,2]. Thus, taken
together, these data suggest that PVT is a major index
of poor prognosis in patients with cirrhosis.
Numerous investigators have studied the prevalence
of non-tumoral PVT, and the mechanisms and/or fac-
tors predicting its occurrence, in patients with cirrhosis
[1–8]. The reported prevalence of non-tumoral portal
vein thrombosis in cirrhosis was highly variable ranging
from 0.6 to 26%, probably due to the diﬀerent groups of
cirrhotic patients studied and the diﬀerent diagnostic
procedures used [1–6]. The study by Zocco et al. in the
present issue of the Journal further addresses this issue
in a series of 73 prospectively followed up, consecutive
patients with cirrhosis, in whom PVT was initially
excluded with US-Doppler [9]. The incidence of de novo0168-8278/$36.00  2009 European Association for the Study of the Liver.
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ble to that reported by Amitrano et al. [4] in a group of
cirrhotic patients followed up prospectively during a
similar period of time. The development of PVT was
more frequent in patients with advanced liver disease,
but a low portal blood ﬂow velocity was the only factor
independently predicting the occurrence of PVT during
follow-up [9].
In previous studies of patients with cirrhosis, male
sex, previous surgery or interventional treatment of por-
tal hypertension, previous variceal bleeding, low platelet
count and advanced liver failure have shown to be asso-
ciated with an increased risk for developing non-tumoral
PVT [1,3,4,6]. All of these ﬁndings have arisen from
cross-sectional studies comparing cirrhotic patients with
or without PVT. In the prospective study by Zocco
et al., patients with a portal blood ﬂow velocity less than
15 cm/s at initial US-Doppler evaluation had a higher
incidence of PVT (47.8%) than those with a portal blood
ﬂow velocity >15 cm/s (2%) [9]. It must be stated, when
considering this cut-oﬀ value, that in the study by Zocco
et al., portal blood velocity was reported as the averaged
maximum value. However, in other studies portal blood
velocity was shown as the mean and not the maximum
value [10–12].
Several aspects in the design of the study under dis-
cussion must be considered. Were patients included in
the study in fact unselected? Therefore, can these data
be extrapolated to the general population of patients
with cirrhosis? Is a reduction in portal blood ﬂow veloc-
ity the best parameter to select cirrhotic patients at high
risk of developing PVT, or can other inherited or
acquired factors substitute or improve its prognostic
capacity? The recruitment of a representative samplePublished by Elsevier B.V. All rights reserved.
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the time of the initial examination is an issue of partic-
ular importance when analyzing prognostic risk factors
for this outcome [13]. Hence, in the study by Zocco
et al., patients with reversed portal blood ﬂow and with
known coagulation disorders other than liver disease,
such as Factor V Leiden mutation or the mutation
20210 of the prothrombin gene, were not enrolled [9].
Exclusion of these patients may have inﬂuenced the
results of the study. Indeed, a study in a large series of
patients with cirrhosis found a prevalence of reversed
ﬂow in the portal venous system of 8.3% [14]. This prev-
alence increased to 12.5% in Child B, and 15% in Child
C, patients. Remarkably, 57% of those patients with
reversed ﬂow in the portal vein trunk had partial PVT
[14].
Similarly, the presence of the 20210 G-A prothrom-
bin gene mutation was found to be associated with an
increased risk of PVT in two cross-sectional studies
[3,7]. More importantly, a prospective follow-up study
of cirrhotic patients without PVT at inclusion showed
PVT to develop signiﬁcantly more frequently in those
patients with the prothrombin gene mutation [4]. How-
ever, no association between prothrombin gene muta-
tion and PVT was demonstrated in another study [8].
However, the latter was a cross-sectional study and
patients with PVT had more severe liver disease than
those without PVT [8,15]. The discrepancy in the ﬁnd-
ings further highlights the importance of patient selec-
tion when looking for prognostic risk factors [13].
Factor V Leiden mutation can be found in 6.7%
[16,17], prothrombinmutation in 2.5% [16] and any inher-
ited prothrombotic conditions in up to 9.1% of healthy
people [16]. Assuming that hereditary coagulation defects
do not decrease – and may even increase – the probability
of having a chronic liver disease [18–20], it is likely that a
similar rate of these inherited alterations will be found in
patients with cirrhosis andmay play a role in the develop-
ment of PVT. Further to these issues regarding patient
selection, is US-Doppler the imaging technique of choice
for excluding PVT at baseline? Eﬃciency of US depends
not only on the expertise of the individual radiologist
but also on the extent of PVT. It is likely that, even in
experienced hands, US-Doppler studies aimed speciﬁ-
cally at evaluating portal venous patency may miss some
patients that already have PVT. Nevertheless, despite the
risk of some false negatives, and due to a better cost or
safety proﬁle in comparison to angioCT or angioMR,
US-Doppler will probably remain the imaging technique
of choice, while angioCT or angioMR should be per-
formed to conﬁrm PVT and determine its extension once
diagnosed with US-Doppler.
It may be argued that, in patients with cirrhosis, pro-
thrombotic disorders, if present, might be counterbal-
anced by the hypocoagulable state related to the
impaired synthesis of procoagulant factors due to liverinsuﬃciency. However, the complex interaction among
procoagulant and anticoagulant mechanisms found in
cirrhosis rarely results in a hypocoagulable state and
bleeding, but may even lead to an hypercoagulable state
[21–23] facilitating PVT. A point of great interest in the
study by Zocco et al. shows that once liver insuﬃciency
and the accompanying decrease in natural anticoagulant
proteins are taken into account, portal blood ﬂow veloc-
ity is a major independent risk factor for PVT. Thus,
one of the components of Virchow’s triad is conﬁrmed
to play a similar role in the splanchnic veins as in other
deep veins. Furthermore, taken together, the ﬁndings of
Zocco et al. and other investigators [3,4,7,24,25] indicate
that, in the presence or absence of cirrhosis, PVT should
be considered a multifactorial disorder resulting from
the combination of inherited and acquired risk factors,
including a reduction in portal blood ﬂow among the
latter.
Measurement of portal blood ﬂow is a quick, easy and
non-invasive procedure and is widely available. There-
fore, a ﬁnding of a reduction in portal blood ﬂow below
the threshold of 15 cm/s may be, alone or in association
to other factors, a useful parameter to consider when eval-
uating the risk of PVT in patients with cirrhosis.
A further word of caution is warranted before extrap-
olating the data by Zocco et al. It should be kept in
mind that over 50% of cirrhotic patients have esopha-
geal varices at diagnosis [26], so a high proportion of
them will be placed on chronic treatment with non-selec-
tive beta-blockers. As these drugs reduce portal blood
ﬂow and velocity [27], it will be interesting to assess
whether reduced portal blood velocity under non-selec-
tive beta-blockers is equally useful in predicting the risk
of developing PVT.
Zocco et al. suggest that patients with a portal blood
velocity below 15 cm/s, may beneﬁt from prophylactic
anticoagulation to prevent PVT. This suggestion is clin-
ically relevant as, according to their data, 31.5% of unse-
lected cirrhotic patients admitted to a teaching hospital
fulﬁlled this criterion, and more than 45% of these are
expected to develop PVT within a year. However, the
risk and beneﬁt of such an approach remains to be
assessed. First, it is still unclear whether the occurrence
of PVT on a low portal ﬂow velocity is an independent
marker for complications and death. Second, it remains
to be ascertained whether anticoagulation in this context
of low portal blood ﬂow velocity will prevent PVT from
developing. Lastly, it should be seen to what extent pre-
vention of portal vein thrombosis in this context of low
portal vein ﬂow velocity is able to impact favorably on
the course of the disease.
Further studies aimed to identify factors that may
help to select cirrhotic patients at high risk of developing
PVT are warranted. These studies should include a large
number of all comers cirrhotic patients in which PVT
and hepatocellular carcinoma must be explicitly
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technique. Clinical and laboratory features, screening
of hereditary and acquired prothrombotic disorders,
and US and US-Doppler parameters at baseline must
be carefully recorded and patients submitted to prospec-
tive follow-up with scheduled imaging studies evaluating
portal vein patency. This will be a necessary step before
designing studies aimed at preventing the development
of PVT.
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